New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - cefuroxime sodium 1.578 g equivalent to 1.5 g cefuroxime;  ;   - powder for injection - 1.5 g - active: cefuroxime sodium 1.578 g equivalent to 1.5 g cefuroxime     - cefuroxime is a bactericidal cephalosporin antibiotic which is resistant to most ?-lactamases and is active against a wide range of gram-positive and gram-negative organisms. it is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. susceptibility to cefuroxime sodium will vary with geography and time and local susceptibility data should be consulted where available. indications include - respiratory tract infections for example, acute exacerbation of chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess and post-operative chest infections. - ear, nose and throat infections for example, sinusitis, tonsillitis, pharyngitis and otitis media. - urinary tract infections for example, acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. - soft-tissue infections for example, cellulitis, erysipelas and wound infections. - bone and joint infections for example, osteomyelitis and septic ar

Canada - English - Health Canada

sterimax inc - cefuroxime (cefuroxime sodium) - powder for solution - 750mg - cefuroxime (cefuroxime sodium) 750mg - second generation cephalosporins

Canada - English - Health Canada

sterimax inc - cefuroxime (cefuroxime sodium) - powder for solution - 1.5g - cefuroxime (cefuroxime sodium) 1.5g - second generation cephalosporins

Canada - English - Health Canada

sterimax inc - cefuroxime (cefuroxime sodium) - powder for solution - 7.5g - cefuroxime (cefuroxime sodium) 7.5g - second generation cephalosporins

United States - English - NLM (National Library of Medicine)

h.j. harkins company, inc. - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 500 mg -   - pharyngitis/tonsillitis caused by streptococcus pyogenes.   note: the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. there are no data from adequate and well-controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin-resistant strains of streptococcus pyogenes.   - acute bacterial otitis media caused by streptococcus pneumoniae , haemophilus influenzae (including beta-lactamase–producing strains), moraxella catarrhalis (including beta-lactamase–producing strains), or streptococcu

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bowmed ibisqus ltd - cefuroxime sodium - powder for solution for injection - 250mg

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes . limitations of use - the efficacy of cefuroxime axetil in the prevention of rheumatic fever was not established in clinical trials. - the efficacy of cefuroxime axetil in the treatment of penicillin-resistant strains of streptococcus pyogenes has not been demonstrated in clinical trials. cefuroxime axetil tablets are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus pneumoniae, haemophilus influenzae (including β-lactamase–producing strains), moraxella catarrhalis (including β-lactamase–producing strains), or streptococcus pyogenes . cefuroxime axetil tablets are indicated for the treatment of adult and pediatric patients (13 years and older) with mild-to-moderate acute bac

United States - English - NLM (National Library of Medicine)

proficient rx lp - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime axetiltablets are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes . limitations of use cefuroxime axetil tablets are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus pneumoniae, haemophilus influenzae (including β-lactamase–producing strains), moraxella catarrhalis (including β-lactamase–producing strains), or streptococcus pyogenes . cefuroxime axetil tablets are indicated for the treatment of adult and pediatric patients (13 years and older) with mild-to-moderate acute bacterial maxillary sinusitis caused by susceptible strains of streptococcus pneumoniae or haemophilus influenzae (non-β -lactamase–producing strains only). limitations of use the effectiveness of cefuroxime axetil for sinus infections caused by β-lactamase–producing ha

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

stravencon ltd. - cefuroxime sodium - eq. cefuroxime 250 mg - powder for solution for infusion - 250 mg - cefuroxime sodium - cefuroxime

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

stravencon ltd. - cefuroxime sodium - eq. cefuroxime 750 mg - powder for solution for infusion - 750 mg - cefuroxime sodium - cefuroxime